tiprankstipranks
Trending News
More News >
TOT BIOPHARM International Co. Ltd. (HK:1875)
:1875
Hong Kong Market
Advertisement

TOT BIOPHARM International Co. Ltd. (1875) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

TOT BIOPHARM International Co. Ltd. has a market cap or net worth of HK$1.68B. The enterprise value is HK$1.44B.
Market CapHK$1.68B
Enterprise ValueHK$1.44B

Share Statistics

TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding772,787,900
Owned by Insiders
Owned by Institutions

Financial Efficiency

TOT BIOPHARM International Co. Ltd.’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 3.54%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.54%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee1.80M
Profits Per Employee56.89K
Employee Count611
Asset Turnover0.73
Inventory Turnover2.91

Valuation Ratios

The current PE Ratio of TOT BIOPHARM International Co. Ltd. is 207.6. TOT BIOPHARM International Co. Ltd.’s PEG ratio is ―.
PE Ratio207.6
PS Ratio0.00
PB Ratio0.00
Price to Fair Value1.67
Price to FCF0.00
Price to Operating Cash Flow45.27
PEG Ratio

Income Statement

In the last 12 months, TOT BIOPHARM International Co. Ltd. had revenue of 1.10B and earned 34.76M in profits. Earnings per share was 0.05.
Revenue1.10B
Gross Profit782.43M
Operating Income41.25M
Pretax Income34.76M
Net Income34.76M
EBITDA84.96M
Earnings Per Share (EPS)0.05

Cash Flow

In the last 12 months, operating cash flow was 27.80M and capital expenditures -68.85M, giving a free cash flow of -41.05M billion.
Operating Cash Flow27.80M
Free Cash Flow-41.05M
Free Cash Flow per Share-0.05

Dividends & Yields

TOT BIOPHARM International Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.56
52-Week Price Change11.00%
50-Day Moving Average2.17
200-Day Moving Average1.92
Relative Strength Index (RSI)42.20
Average Volume (3m)506.89K

Important Dates

TOT BIOPHARM International Co. Ltd. upcoming earnings date is Mar 24, 2026, TBA (Not Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateMar 24, 2026
Ex-Dividend Date

Financial Position

TOT BIOPHARM International Co. Ltd. as a current ratio of 1.79, with Debt / Equity ratio of 54.20%
Current Ratio1.79
Quick Ratio1.53
Debt to Market Cap0.32
Net Debt to EBITDA0.17
Interest Coverage Ratio0.00

Taxes

In the past 12 months, TOT BIOPHARM International Co. Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

TOT BIOPHARM International Co. Ltd. EV to EBITDA ratio is 14.52, with an EV/FCF ratio of 0.00.
EV to Sales1.12
EV to EBITDA14.52
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00

Balance Sheet

TOT BIOPHARM International Co. Ltd. has HK$381.26M in cash and marketable securities with HK$395.47M in debt, giving a net cash position of HK$14.21M billion.
Cash & Marketable SecuritiesHK$381.26M
Total DebtHK$395.47M
Net CashHK$14.21M
Net Cash Per ShareHK$0.02
Tangible Book Value Per ShareHK$1.00

Margins

Gross margin is 71.24%, with operating margin of 3.76%, and net profit margin of 3.16%.
Gross Margin71.24%
Operating Margin3.76%
Pretax Margin3.16%
Net Profit Margin3.16%
EBITDA Margin7.74%
EBIT Margin4.20%

Analyst Forecast

The average price target for TOT BIOPHARM International Co. Ltd. is HK$3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$3.00
Price Target Upside37.61% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast9.41%
EPS Growth Forecast-32.69%

Scores

Smart Score5
AI Score71
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis